Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 1;2(8):902-907.
doi: 10.1001/jamacardio.2017.0538.

Effect of Resveratrol on Walking Performance in Older People With Peripheral Artery Disease: The RESTORE Randomized Clinical Trial

Mary M McDermott  1   2   3 , Christiaan Leeuwenburgh  4 , Jack M Guralnik  5 , Lu Tian  6 , Robert Sufit  7 , Lihui Zhao  2 , Michael H Criqui  8 , Melina R Kibbe  9   10 , James H Stein  11 , Donald Lloyd-Jones  2 , Stephen D Anton  4 , Tamar S Polonsky  12 , Ying Gao  2 , Rafael de Cabo  13 , Luigi Ferrucci  13
Affiliations
Randomized Controlled Trial

Effect of Resveratrol on Walking Performance in Older People With Peripheral Artery Disease: The RESTORE Randomized Clinical Trial

Mary M McDermott et al. JAMA Cardiol. .

Abstract

Importance: Research shows that resveratrol, a sirtuin activator in red wine, improves exercise endurance and skeletal-muscle oxidative metabolism in animals and may enhance vascular function in humans. Resveratrol supplement sales exceed $30 million annually in the United States, but few data are available regarding its efficacy in humans.

Objective: To determine whether resveratrol, 125 mg/d or 500 mg/d, improves the 6-minute walk performance in patients with peripheral artery disease (PAD).

Design, setting, and participants: This parallel-design, double-blind, randomized clinical trial, called Resveratrol to Improve Outcomes in Older People With PAD (RESTORE), was conducted at Northwestern University. Sixty-six participants 65 years or older with PAD were randomized to receive a daily capsule of resveratrol, 125 mg or 500 mg, or placebo for 6 months. Participants were randomized using a randomly permuted block method stratified by baseline 6-minute walk test performance. This trial was conducted between January 1, 2015, and August 5, 2016, and data analyses were performed according to the intention-to-treat concept.

Interventions: Administration of resveratrol, 125 or 500 mg/d, or placebo once daily.

Main outcomes and measures: The primary outcome measure was the change in 6-minute walk distance at the 6-month follow-up. One of the secondary outcomes was change in maximal treadmill walking time. Because of the preliminary nature of the trial, the a priori power calculation used a 1-sided test with a significance level of P < .10.

Results: The 66 participants were predominantly men (45 [68%]), had a mean (SD) age of 74.4 (6.6) years, and had a mean (SD) ankle brachial index of 0.67 (0.18). Sixty-four (97%) completed follow-up. Six-month mean (SE) changes in 6-minute walk distance were 4.6 (8.1) m for the 125-mg resveratrol group, -12.8 (7.5) m for the 500-mg resveratrol group, and -12.3 (7.9) m for the placebo group (P = .07 for the 125-mg resveratrol group vs placebo; P = .96 for the 500-mg resveratrol group vs placebo). Six-month mean (SE) changes in maximal treadmill walking time were 0.5 (2.3) minutes for the 125-mg resveratrol group, -0.6 (2.1) minutes for the 500-mg resveratrol group, and 0.4 (2.1) minutes for the placebo group (P = .18 for the 125-mg resveratrol group vs placebo; P = .12 for the 500-mg resveratrol group vs placebo).

Conclusions and relevance: The RESTORE trial found no consistent evidence that resveratrol improves walking performance in patients 65 years or older with PAD.

Trial registration: clinicaltrials.gov Identifier: NCT02246660.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Figures

Figure.
Figure.. CONSORT Flow Diagram
Summary of randomized participants and follow-up rates in the RESTORE randomized clinical trial. ABI indicates ankle brachial index.
See this image and copyright information in PMC

References

    1. Lin Y, Chen F, Zhang J, et al. . Neuroprotective effect of resveratrol on ischemia/reperfusion injury in rats through TRPC6/CREB pathways. J Mol Neurosci. 2013;50(3):504-513. - PubMed
    1. Menzies KJ, Singh K, Saleem A, Hood DA. Sirtuin 1–mediated effects of exercise and resveratrol on mitochondrial biogenesis. J Biol Chem. 2013;288(10):6968-6979. - PMC - PubMed
    1. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2011;21(11):851-856. - PubMed
    1. Timmers S, Konings E, Bilet L, et al. . Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622. - PMC - PubMed
    1. Kumar V, Pandey A, Jahan S, et al. . Differential responses of trans-resveratrol on proliferation of neural progenitor cells and aged rat hippocampal neurogenesis. Sci Rep. 2016;6:28142. - PMC - PubMed

Publication types

Associated data